CRESCENT BIOPHARMA, INC. (CBIO): restructuring charge — GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan

CRESCENT BIOPHARMA, INC.

FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.
Workforce reduced by 26 employees (~80%); expects $3.6M in severance charges in Q3 2024.
CMO Dr. Edwin Rock departs July 31; will receive 12 months' base salary severance and consulting deal.
Cash and equivalents ~$31.3M as of March 31; restructuring extends cash runway into Q2 2025.
Engaged Lucid Capital Markets to explore strategic alternatives including sale, merger, or licensing.

item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Edwin Rock

Chief Medical Officer

CBIO · CRESCENT BIOPHARMA, INC.

Effective: 2024-07-31
Filed: July 30, 2024, 7:59 PM ET

the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Edwin Rock departed as Chief Medical Officer at CRESCENT BIOPHARMA, INC..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

CRESCENT BIOPHARMA, INC. announced a restructuring with charges of approximately $3.6 million (reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount).

Type: restructuring
Charge: approximately $3.6 million
Headcount: reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount

Exact text from the filing

in connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring that includes a reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount. The Company expects to substantially complete the reduction by July 31, 2024. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-010370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.